• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Antibody breadth and protective efficacy is increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutini

tetano

Editor, Senior Moderator
Clin Vaccine Immunol. 2011 Dec 21. [Epub ahead of print]
ANTIBODY BREADTH AND PROTECTIVE EFFICACY IS INCREASED BY VACCINATION WITH COMPUTATIONALLY OPTIMIZED HEMAGGLUTININ BUT NOT WITH POLYVALENT HEMAGGLUTININ BASED H5N1 VLP VACCINES.
Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM.
Source

Center for Vaccine Research.
Abstract

One of the challenges for developing an H5N1 influenza vaccine is the diversity of antigenically distinct isolates within this subtype. Previously, our group described a novel hemagglutinin derived from a methodology termed computationally optimized broadly reactive antigen (COBRA). This COBRA HA, when used as an immunogen, elicits a broad antibody response against H5N1 isolates from different clades. In this report, the immune responses elicited by the COBRA HA virus-like particle (VLP) vaccine were compared to responses elicited by a mixture of VLPs expressing representative HA molecules from clade 2.1, 2.2, and 2.3 primary H5N1 isolates (polyvalent). COBRA HA VLP elicited higher titer antibodies to a panel of H5N1 HA proteins. Both COBRA and polyvalent vaccines protected vaccinated mice and ferrets from experimental infection with highly lethal H5N1 influenza viruses, but COBRA vaccinated animals had decreased viral replication, less inflammation in the lungs of mice, and reduced virus recovery in ferret nasal washes. Both vaccines had similar cellular responses post-challenge indicating that higher titer serum antibody likely restricts the duration of viral replication. Furthermore, passively transferred immune serum from COBRA HA VLP vaccinated mice protected recipient animals more efficiently than immune serum from polyvalent vaccinated mice. This is the first report comparing these two vaccine strategies. The single COBRA HA antigen elicited a broader antibody response and reduced morbidity and viral titers more effectively than a polyvalent mixture of primary H5N1 HA antigens.

PMID:
22190399
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22190399
 
Back
Top Bottom